Preclinical evaluation of engineered L-asparaginase variants to improve the treatment of Acute Lymphoblastic Leukemia

Preclinical evaluation of engineered L-asparaginase variants to improve the treatment of Acute Lymphoblastic Leukemia

Introduction: Escherichia coli l-asparaginase (EcA), an integral part of multi-agent chemotherapy protocols of acute lymphoblastic leukemia (ALL), is constrained by safety concerns and the development of anti-asparaginase antibodies. Novel variants with better pharmacological properties are desirabl...

Full description

Bibliographic Details
Main Authors: Soumika Sengupta, Mainak Biswas, Khushboo A. Gandhi, Saurabh Kumar Gupta, Poonam B. Gera, Vikram Gota, Avinash Sonawane
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:Translational Oncology
Subjects:
L-asparaginase
Acute lymphoblastic leukemia
Immunogenicity
Efficacy
Half-life
Glutaminase activity
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523324000342

Internet

http://www.sciencedirect.com/science/article/pii/S1936523324000342

Similar Items